DNL343 Shows Promise as First-in-Class eIF2B Activator for ALS Treatment in Phase 1 Clinical Trial
核心洞察
DNL343, an investigational eIF2B (搜索) activator, successfully modulated the integrated stress response (ISR) in both preclinical ALS (搜索) models and human clinical trials, demonstrating target engagement and biological activity.
The compound prevented stress granule formation and reduced TDP-43 pathology in cellular and mouse models, while showing transient improvements in motor function and reduced neurodegeneration markers.
Phase 1 and 1b clinical trials in healthy volunteers and ALS (搜索) patients confirmed DNL343's safety profile, brain penetration, and ability to inhibit ISR activity through peripheral biomarkers.
A novel investigational compound targeting a fundamental cellular stress pathway has demonstrated promising results in preclinical models of amyotrophic lateral sclerosis (搜索) (ALS (搜索)) and advanced to successful Phase 1 clinical testing. DNL343, developed as an activator of the eIF2B (搜索) complex, represents a first-in-class approach to modulating the integrated stress response (ISR) in neurodegenerative diseases (搜索).
Targeting the Integrated Stress Response in ALS
The integrated stress response serves as a critical cellular mechanism for maintaining protein homeostasis under various stress conditions. In ALS (搜索) and related neurodegenerative disorders, dysregulation of this pathway contributes to neuronal dysfunction and death. DNL343 specifically activates eIF2B (搜索), a guanine nucleotide exchange factor essential for protein synthesis initiation, potentially restoring cellular balance in disease states.
Research published in Nature Communications demonstrates that DNL343 effectively prevented ISR activation induced by cytoplasmic TDP-43 expression and C9orf72 hexanucleotide repeat expansions, two major pathological hallmarks of ALS (搜索). In engineered cell lines expressing disease-associated proteins, DNL343 treatment prevented upregulation of ISR markers including ATF4 (搜索) protein and downstream gene targets such as CHAC1, ATF3, and DDIT3.
Stress Granule Modulation and Neuroprotection
A key finding involved DNL343's ability to prevent stress granule formation, pathological protein aggregates that contribute to neuronal dysfunction in ALS (搜索). In cellular models, the compound prevented formation of new stress granules and dissolved pre-existing ones, with over 90% colocalization between cytoplasmic TDP-43 and stress granule markers being eliminated upon treatment.
Super-resolution microscopy revealed that cytoplasmic TDP-43 associates with both the periphery and core of stress granules marked by G3BP1, ATXN2, and UBAP2L. DNL343 pretreatment maintained diffuse localization of these proteins despite stress-inducing conditions, suggesting restoration of normal cellular organization.
Preclinical Efficacy in ALS Mouse Models
The rNLS8 transgenic mouse model, which expresses cytoplasmic human TDP-43 and develops ALS (搜索)-like phenotypes, served as the primary preclinical testing platform. Acute dosing with DN9058 (搜索), a brain-penetrant analog of DNL343, significantly reduced ISR markers including phosphorylated eIF2α (搜索) and ATF4 (搜索) protein levels in mouse brains at 2 weeks off doxycycline.
Chronic treatment over 6 weeks demonstrated sustained ISR inhibition and transient functional improvements. DN9058 (搜索)-treated mice showed delayed progression to hindlimb clasping (median 2.3 vs 2.0 weeks), improved rotarod performance, and enhanced grip strength at 2 weeks. Importantly, plasma neurofilament light levels, a marker of neurodegeneration, were significantly lower in treated animals at 4 weeks.
Clinical Validation in Human Studies
Phase 1 clinical trials enrolled healthy volunteers in single ascending dose (15-800 mg) and multiple ascending dose (45-260 mg daily for 14 days) cohorts. DNL343 demonstrated favorable pharmacokinetics with dose-proportional exposure, long half-life (31-46 hours), and excellent brain penetration with CSF-to-unbound plasma ratios of 0.689-0.795.
The Phase 1b study in 29 ALS (搜索) patients evaluated 100 mg and 200 mg daily doses for 28 days. DNL343 achieved robust target engagement, with the 200 mg dose producing approximately 80% median reduction in both ATF4 (搜索) protein and CHAC1 gene expression in stimulated peripheral blood mononuclear cells. CSF GDF-15 (搜索) levels, an ISR-related biomarker, decreased by approximately 10% in both dose groups.
Safety Profile and Tolerability
DNL343 demonstrated a favorable safety profile across all clinical studies. In healthy volunteers, treatment-emergent adverse events occurred at similar frequencies between DNL343 (64-91%) and placebo (67-92%) groups, with most events being mild in severity. The most common adverse events were postural dizziness in single-dose studies and headache in multiple-dose studies.
In ALS (搜索) patients, DNL343 was well tolerated with no deaths, serious adverse events, or severe adverse events reported. The most frequent treatment-related adverse events were headache (37% vs 22% placebo), fatigue (32% vs 22%), and taste disturbance (11% vs 0%). Only one participant discontinued due to a Grade 2 rash in the 200 mg group.
Biomarker Validation in Human ALS
Analysis of spinal cord tissue from ALS (搜索) patients confirmed ISR pathway activation in human disease. The ISR gene set showed significant upregulation in cervical (p-value: 0.0006) and lumbar (p-value: 0.0161) spinal cord regions compared to healthy controls, with genes including BCL2L11, CEBPA, MTHFD2, and SLC1A5 showing the most significant increases.
CSF GDF-15 (搜索) protein concentrations were elevated in ALS (搜索) patients compared to healthy volunteers, both before and after age adjustment, supporting its utility as a biomarker for ISR activation in the central nervous system. This finding validates the translational relevance of preclinical observations and provides a potential pharmacodynamic marker for future studies.
Implications for ALS Treatment
The successful translation of DNL343 from preclinical models to human clinical testing represents a significant advancement in ALS (搜索) drug development. Unlike approaches targeting downstream disease effects, eIF2B (搜索) activation addresses fundamental cellular dysfunction at the level of protein synthesis regulation.
The compound's ability to cross the blood-brain barrier effectively, engage its target in the central nervous system, and demonstrate biological activity through validated biomarkers establishes a foundation for larger efficacy studies. The transient but measurable functional improvements in preclinical models, combined with biomarker evidence of neuroprotection, suggest potential for disease modification rather than merely symptomatic treatment.
Future Development Pathway
While the current studies establish proof-of-concept for eIF2B (搜索) activation in ALS (搜索), longer-term clinical trials will be necessary to determine whether ISR modulation can provide sustained clinical benefits. The identification of peripheral biomarkers responsive to DNL343 treatment provides tools for monitoring target engagement and optimizing dosing in future studies.
The research also suggests broader applications beyond ALS (搜索), as ISR dysregulation is implicated in multiple neurodegenerative diseases (搜索) including Alzheimer's disease (搜索) and frontotemporal dementia (搜索). The mechanistic approach of restoring cellular homeostasis through eIF2B (搜索) activation may represent a platform technology applicable across the spectrum of protein misfolding disorders.